Compare · CTIC vs NVO
CTIC vs NVO
Side-by-side comparison of CTI BioPharma Corp. (DE) (CTIC) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTIC and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $220.35B, about 1150.9x CTIC ($191.5M).
- NVO has hit the wire 5 times in the past 4 weeks while CTIC has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 7 for CTIC).
- Company
- CTI BioPharma Corp. (DE)
- Novo Nordisk A/S
- Price
- $9.09-0.05%
- $41.18+6.93%
- Market cap
- $191.5M
- $220.35B
- 1M return
- -
- +13.32%
- 1Y return
- -
- -34.24%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 0
- 5
- Recent ratings
- 7
- 25
CTI BioPharma Corp. (DE)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CTIC
- SEC Form 15-12G filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S